Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients
Authors:
- Hideaki AndohHAHideaki Andoh
- Makio GamohMGMakio Gamoh
- Takuhiro YamaguchiTYTakuhiro Yamaguchi
- Yasuko MurakawaYMYasuko Murakawa
- Hideki ShimodairaHSHideki Shimodaira
- Shin TakahashiSTShin Takahashi
- Takahiro MoriTakahiro Mori
- Hisatsugu OhoriHOHisatsugu Ohori
- Shun-Ichi MaedaSMShun-Ichi Maeda
- Takao SuzukiTSTakao Suzuki
- Satoshi KatoSKSatoshi Kato
- 1 July 2012
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 83 (2) , 101-107
Abstract
Objective: S-1 is effective in sequential combination with irinotecan (IRIS) in treating metastatic colorectal cancer. We conducted a randomized phase II trial of modified leucovorin, fluorouracil and irinotecan (mFOLFIRI) + bevacizumab and sequential IRIS + bevacizumab as first- or second-line therapies. Methods: Sixty metastatic colorectal cancer patients were randomly assigned to receive mFOLFIRI + bevacizumab or sequential IRIS + bevacizumab (7.5 mg/kg of bevacizumab and 150 mg/m2 of irinitecan, and 80 mg/m2/day of S-1 orally from day 3 until day 16 as a 3-week course). The primary endpoint was the safety of each method until week 12, with the secondary endpoint being the comparison of the safety and efficacy of the two methods. Results: The safety of the two treatments was comparable, except that G3 anorexia and diarrhoea were less frequent with sequential IRIS + bevacizumab. The overall response rate was 62% [95% confidence interval (CI) 40.1–79.8] versus 72% (95% CI 50.6–86.2), and progression-free survival was 324 days (95% CI 247–475) versus 345 days (95% CI 312–594) with mFOLFIRI + bevacizumab versus IRIS + bevacizumab, respectively. Conclusion: Sequential IRIS + bevacizumab is a safe and effective method of systemic chemotherapy against metastatic colorectal cancer and is compatible with mFOLFIRI + bevacizumab.Keywords
This publication has 17 references indexed in Scilit:
- Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort StudyThe Oncologist, 2009
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnnals of Oncology, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C StudyJournal of Clinical Oncology, 2007
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer PatientsJournal of Clinical Oncology, 2003
- Infectious Morbidity Associated with Long-Term Use of Venous Access Devices in Patients with CancerAnnals of Internal Medicine, 1993